Did patients overall prefer SCIg treatment to IVIg treatment?
According to a 36-question survey conducted in the Canadian and the non-IND European clinical studies, 80% of the patients in the Phase III clinical trial preferred SCIg treatment to IVIg. Often-cited reasons for the preference of SCIg included greater independence, better therapy convenience, less interference with work and/or school and lower travel costs.